” These exciting results suggest that there may be a novel system for accomplishing weight loss with an extensive loss of body fat and a boost in lean mass, along with other metabolic benefits,” said Steve Heymsfield, MD, FTOS, previous president of The Obesity Society and corresponding author of the research study. At the end of the 48-week study, researchers found an almost 21 percent reduction in body fat in the Bimagrumab group compared to 0.5 percent in the placebo group. Coleman, Miller, Rooks, Roubenoff, Laurent, Praestgaard, Petricoul and Swan reported being employees of Novartis Institutes for Biomedical Research during the conduct of the study. Goodpaster reported getting personal fees from Novartis for work carried out throughout the conduct of the study.
. A total of 75 clients with type 2 diabetes, body mass index between 28 and 40, and glycated hemoglobin A1c levels between 6.5 percent and 10 percent were chosen for the phase 2 randomized scientific trial. Clients were injected with either Bimagrumab or a placebo (a dextrose service) every 4 weeks for 48 weeks. Both groups received diet plan and exercise counseling. The research study happened at 9 websites in the United States and the United Kingdom from February 2017 to May 2019.
At the end of the 48-week study, researchers found a nearly 21 percent decrease in body fat in the Bimagrumab group compared to 0.5 percent in the placebo group. The results also exposed the Bimagrumab group got 3.6 percent of lean mass compared with a loss of 0.8 percent in the placebo group. The combined loss in overall body fat and gain in lean mass led to a net 6.5 percent reduction in body weight in patients getting Bimagrumab compared with 0.8 percent weight reduction in their counterparts getting the placebo.
The sample size of 75 participants was a restriction of the research study. There was also a gender imbalance throughout the groups with more ladies randomized to Bimagrumab and more males to the placebo.
Partial outcomes of this study existed throughout a research online forum titled “Emerging Pharmacological Anti-obesity Therapies” at ObesityWeek ® 2019 in Las Vegas, Nev
. Recommendation: “Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial” by Steven B. Heymsfield, MD; Laura A. Coleman, PhD, RD; Ram Miller, MD; Daniel S. Rooks, PhD; Didier Laurent, PhD; Olivier Petricoul, PhD; Jens Praestgaard, PhD; Therese Swan, PharmD; Thomas Wade, MD; Robert G. Perry, MD; Bret H. Goodpaster, PhD and Ronenn Roubenoff, MD, MHS, 13 January 2021, JAMA Network Open.DOI: 10.1001/ jamanetworkopen.2020.33457.
Other authors of the research study consist of Laura Coleman, Ram Miller, Daniel Rooks, Jens Praestgaard, and Therese Swan, Translational Medicine, Novartis Institutes for Biomedical Research, Cambridge, Mass. Didier Laurent, Olivier Petricoul, and Ronenn Roubenoff, Translational Medicine, Novartis Institutes of Biomedical Research in Basel, Switzerland, along with Thomas Wade of QPS-Miami Research Associates in Miami, Fla; Robert Perry of Panax Clinical Research of Miami; and Bret Goodpaster of Advent Health Research Institute in Orlando, Fla., also co-authored the study.
Heymsfield reported receiving individual costs from Tanita and Medifast outside of the sent work. Coleman, Miller, Rooks, Roubenoff, Laurent, Praestgaard, Petricoul and Swan reported being employees of Novartis Institutes for Biomedical Research throughout the conduct of the research study. Coleman and Roubenoff reported having a patent for PAT058683-US-PSP pending with Novartis. Rooks and Roubenoff reported being co-authors of a patent for use of Bimagrumab in other indicators that is no longer being developed. Goodpaster reported receiving personal fees from Novartis for work performed during the conduct of the study. No other disclosures were reported.
A new research study confirms that treatment with Bimagrumab, an antibody that obstructs activin type II receptors and promotes skeletal muscle development, is safe and efficient for treating excess adiposity and metabolic disturbances of adult patients with weight problems and type 2 diabetes.
” These amazing results recommend that there might be a novel mechanism for accomplishing weight reduction with a profound loss of body fat and an increase in lean mass, in addition to other metabolic benefits,” stated Steve Heymsfield, MD, FTOS, past president of The Obesity Society and matching author of the study. Heymsfield is professor and director of the Metabolism and Body Composition Laboratory at the Pennington Biomedical Research Center in Baton Rouge, La
